Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Apixaban

Akanksha Agrawal  1 , Biagio Manna  2
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Apixaban

Akanksha Agrawal et al.
Free Books & Documents

Excerpt

Apixaban is a novel oral anticoagulant approved by the US Food and Drug Administration (FDA) in 2012 for use in patients with nonvalvular atrial fibrillation to reduce the risk of stroke and blood clots. Later, in 2014, apixaban gained approval for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for reducing the risk of blood clots (DVT and PE) in patients who have undergone knee or hip replacement surgery. The drug is also approved for reducing the risk of recurrent DVT and PE after initial therapy.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Akanksha Agrawal declares no relevant financial relationships with ineligible companies.

Disclosure: Biagio Manna declares no relevant financial relationships with ineligible companies.

References

    1. Skelley JW, Thomason AR, Hammond LN. Extended-Duration Use of Direct Oral Anticoagulants to Prevent VTE in Acutely III Medical Patients. Sr Care Pharm. 2019 Feb 01;34(2):99-108. - PubMed
    1. Powell J, Taylor J, Garland SG. Andexanet alfa: A Novel Factor Xa Inhibitor Reversal Agent. Ann Pharmacother. 2019 Sep;53(9):940-946. - PubMed
    1. Knotts TL, Mousa SA. Anticoagulation in Venous Thromboembolism Prophylaxis in Medically Ill Patients: Potential Impact of NOACs. Am J Cardiovasc Drugs. 2019 Aug;19(4):365-376. - PubMed
    1. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019 Jul 09;140(2):e125-e151. - PubMed
    1. Barrett YC, Wang J, Knabb R, Mohan P. Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thromb Haemost. 2011 Jan;105(1):181-9. - PubMed

Publication types

LinkOut - more resources